다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Oncology letters, v.9 no.5, 2015년, pp.2353 - 2360
QIAO, ZHENGUO , YUAN, JIGANG , SHEN, JIAQING , WANG, CHAO , HE, ZHILONG , HU, YIJIA , ZHANG, MUXING , XU, CHUNFANG
AI-Helper
Pancreatic cancer is one of the most frequently occurring malignancies worldwide and it is the fourth most common cause of cancer-associated mortality in Western countries. Thalidomide (THD) plays an important role in tumor therapy, as it is able to promote early stage apoptosis and inhibit the proc...
CA Cancer J Clin Jemal 60 277 2010 10.3322/caac.20073 Cancer statistics, 2010
J Gastrointest Surg Ferrone 12 701 2008 10.1007/s11605-007-0384-8 Pancreatic adenocarcinoma: The actual 5-year survivors
J Clin Oncol Burris 15 2403 1997 10.1200/JCO.1997.15.6.2403 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
Neoplasia Hagmann 12 740 2010 10.1593/neo.10576 Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells
Teratology McBride 16 79 1977 10.1002/tera.1420160113 Thalidomide embryopathy
Proc Natl Acad Sci USA D'Amato 91 4082 1994 10.1073/pnas.91.9.4082 Thalidomide is an inhibitor of angiogenesis
N Engl J Med Singhal 341 1565 1999 10.1056/NEJM199911183412102 Antitumor activity of thalidomide in refractory multiple myeloma
Urol J Rezvani 9 673 2012 Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer
Cancer Biol Med Lv 9 111 2012 A Randomised Controlled Phase II Trial of the Combination of XELOX with Thalidomide for the First-line Treatment of Metastatic Colorectal Cancer
Cancer Med Lee 2 360 2013 10.1002/cam4.74 A potential new enriching trial design for selecting non-small-cell lung cancer patients with no predictive biomarker for trials based on both histology and early tumor response: Further analysis of a thalidomide trial
Biomed Pharmacother de Souza 68 51 2014 10.1016/j.biopha.2013.08.004 Combination therapy with carboplatin and thalidomide suppresses tumor growth and metastasis in 4T1 murine breast cancer model
J Pak Med Assoc Tunio 62 876 2012 Low-dose thalidomide in patients with metastatic renal cell carcinoma
Neoplasma Dmoszynska 52 175 2005 The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma
Cancer Res Marriott 63 593 2003 A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins
Cancer Res Georgakoudi 64 5044 2004 10.1158/0008-5472.CAN-04-1058 In vivo flow cytometry: a new method for enumerating circulation cancer cells
Vet Res Commun. Forni 31 43 2007 10.1007/s11259-007-0096-2 Laboratory animals science: a resource to improve the quality of science
Blood Yabu 106 125 2005 10.1182/blood-2004-09-3679 Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate
World J Gastroenterol Zhang 11 216 2005 10.3748/wjg.v11.i2.216 Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice
Blood Steins 99 834 2002 10.1182/blood.V99.3.834 Efficacy and safety of thalidomide in patients with acute myeloid leukemia
Hematol J Liu 5 247 2004 10.1038/sj.thj.6200351 s-thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line
Adv Exp Med Biol Estaquier 942 157 2012 10.1007/978-94-007-2869-1_7 The mitochondrial pathways of apoptosis
Pancreatology Shen 12 91 2012 10.1016/j.pan.2012.02.008 miR-15b and miR-16 induce the apoptosis of rat activated pancreatic stellate cells by targeting Bcl-2 in vitro
Exp Cell Res Sung 315 1975 2009 10.1016/j.yexcr.2009.01.009 Prosurvival Bcl-2 proteins stabilize pancreatic mitochondria and protect against necrosis in experimental pancreatitis
Mol Cell Endocrinol Barbu 190 75 2002 10.1016/S0303-7207(02)00009-6 Cytokine-induced apoptosis and necrosis are preceded by disruption of the mitochondrial membrane potential (Deltapsi(m)) in pancreatic RINm5F cells: Prevention by Bcl-2
Graefes Arch Clin Exp Ophthalmol Aydoan 246 363 2008 10.1007/s00417-007-0663-9 The effect of thalidomide on vascular endothelial growth factor and tumor necrosis factor-alpha levels in retinal ischemia/reperfusion injury
Nature Coultas 438 937 2005 10.1038/nature04479 Endothelial cells and VEGF in vascular development
Oncol Res Giatromanolaki 12 33 2000 10.3727/000000001108747426 Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer
Biomed Pharmacother Xu 67 133 2013 10.1016/j.biopha.2012.10.005 Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance
J Clin Oncol Colucci 28 1645 2010 10.1200/JCO.2009.25.4433 Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC): Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: The GIP-1 study
J Clin Oncol Herrmann 25 2212 2007 10.1200/JCO.2006.09.0886 Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
J Clin Oncol Abou-Alfa 24 4441 2006 10.1200/JCO.2006.07.0201 Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer
Ann Oncol Chauffert 19 1592 2008 10.1093/annonc/mdn281 Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.